Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01498159 · ClinicalTrials.gov registry record · NA
Health Promoters and Pharmacists in Diabetes Team Management
A NA study of Diabetes Mellitus, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- NA
- Development phase
- 244
- Enrollment target
- 1
- Study location
NCT01498159: Completed NA study of Diabetes Mellitus, sponsored by University of Illinois at Chicago.
NCT01498159 is a NA study of Diabetes Mellitus that has completed, run by University of Illinois at Chicago. The registered enrollment target is 244 participants, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01498159, a NA study of Diabetes Mellitus, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- NA
- Development phase
- 244 participants
- Enrollment target
- 1
- Study location
Study Summary
This research evaluates a diabetes management intervention designed to improve medication adherence and intensify therapy to reach goals in blood sugar, blood pressure, and cholesterol levels. This study will determine the benefit and cost of adding community health promoters to pharmacist disease management services. If there is benefit, then this approach may help reduce the burden of diabetes and its related complications among minorities with diabetes.
Primary Outcome
Hemoglobin A1c
Conditions Studied
Interventions
- BEHAVIORAL Pharmacist disease/medication management
- BEHAVIORAL Pharmacist-patient encounters
- BEHAVIORAL Pharmacist medication intensification and adherence support
- BEHAVIORAL Pharmacist communication with primary care physicians
- BEHAVIORAL Pharmacist documentation in electronic medical record
Study Locations (1)
Illinois
- University of Illinois Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2011-12 |
| Est. Completion | 2018-01 |
| Phase | NA |
What the finished NCT01498159 record still lists
NCT01498159 is an interventional study that assigns participants to a tested intervention. The registered 244 participants enrollment target is mid-sized for trials with a published cap, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 5 interventions - of which Pharmacist disease/medication management is the first listed.
NCT01498159 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT01498159 about?
NCT01498159 is a clinical study titled "Health Promoters and Pharmacists in Diabetes Team Management". This research evaluates a diabetes management intervention designed to improve medication adherence and intensify therapy to reach goals in blood sugar, blood pressure, and cholesterol levels. This study will determine the benefit and cost of adding community health promoters to pharmacist disease m...
What is the current status of trial NCT01498159?
This trial is currently completed. It is a NA study. The enrollment target is 244 participants. The study started on 2011-12. Estimated completion is 2018-01.
What conditions does trial NCT01498159 study?
This clinical trial studies the following conditions: Diabetes Mellitus.
What interventions are being tested in trial NCT01498159?
The interventions under investigation include: Pharmacist disease/medication management (BEHAVIORAL), Pharmacist-patient encounters (BEHAVIORAL), Pharmacist medication intensification and adherence support (BEHAVIORAL), Pharmacist communication with primary care physicians (BEHAVIORAL), Pharmacist documentation in electronic medical record (BEHAVIORAL).
Who is sponsoring clinical trial NCT01498159?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01498159 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01498159's enrollment target sits among peer trials
244 81st of 208 higher than 128 of 208 other Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Glycemic Control With Telemedicine and Smart Insulin Pens
RECRUITING · NA
-
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
RECRUITING · NA
-
Therapeutic Plantar Electrical Stimulation Intervention During Hemodialysis to Improve Balance and Mobility
RECRUITING · NA
-
FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
RECRUITING · NA
-
Innovative Multi-Variable Biofeedback for Improving Gait Performance in Individuals With Diabetic Peripheral Neuropathy
RECRUITING · NA
-
Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02227251 · 244 participants · Phase 2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT04317534 · 244 participants · Phase 2
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
- NCT04683250 · 244 participants · Phase 1
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
- NCT04686305 · 244 participants · Phase 1
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia